Banff 2013 update: Pearls and pitfalls in transplant renal pathology

Nephrology

Volumn 20, Issue S2, 2015, Pages 2-8

  Hara, Shigeo ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

C4d; isolated v lesion; polyomavirus BK nephropathy; transplant glomerulitis; transplant glomerulopathy

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C4D; DONOR SPECIFIC ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ARTERITIS; BK VIRUS; CELL DAMAGE; CHRONIC GRAFT REJECTION; CLINICAL PRACTICE; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; GENE EXPRESSION; GLOMERULITIS; GLOMERULONEPHRITIS; GLOMERULOPATHY; GOLD STANDARD; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; KIDNEY GRAFT; MICROVASCULARIZATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SIMIAN VIRUS 40; T LYMPHOCYTE; VIRUS LOAD; ADVERSE EFFECTS; ALLOGRAFT; BIOPSY; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; GRAFT REJECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; KIDNEY; KIDNEY TRANSPLANTATION; PATHOLOGY; POLYOMAVIRUS; POLYOMAVIRUS INFECTION; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS INFECTION;

ALLOGRAFTS; BIOMARKERS; BIOPSY; COMPLEMENT C4B; DIAGNOSIS, DIFFERENTIAL; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY TRANSPLANTATION; PEPTIDE FRAGMENTS; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME; TUMOR VIRUS INFECTIONS; VIRAL LOAD;

EID: 84930345205     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12474     Document Type: Review

References (37)

1. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 2014; 14: 272-283.
2. Solez K, Colvin RB, Racusen LC, et al. Banff ′05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am. J. Transplant. 2007; 7: 518-526.
3. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF,. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am. J. Transplant. 2009; 9: 2312-2323.
4. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am. J. Transplant. 2009; 9: 2561-2570.
5. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am. J. Transplant. 2008; 8: 753-760.
6. Jen KY, Nguyen TB, Vincenti FG, Laszik ZG,. C4d/CD34 double-immunofluorescence staining of renal allograft biopsies for assessing peritubular capillary C4d positivity. Mod. Pathol. 2012; 25: 434-438.
7. Farkash EA, Colvin RB,. Diagnostic challenges in chronic antibody-mediated rejection. Nat. Rev. Nephrol. 2012; 8: 255-257.
8. Magil AB, Tinckam K,. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int. 2003; 63: 1888-1893.
9. Magil AB,. Infiltrating cell types in transplant glomerulitis: relationship to peritubular capillary C4d deposition. Am. J. Kidney Dis. 2005; 45: 1084-1089.
10. Buob D, Grimbert P, Glowacki F, et al. Three-year outcome of isolated glomerulitis on 3-month protocol biopsies of donor HLA antibody negative patients. Transpl. Int. 2012; 25: 663-670.
11. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55: 713-723.
12. Batal I, Lunz JG 3rd, Aggarwal N, et al. A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am. J. Transplant. 2010; 10: 2442-2452.
13. Wavamunno MD, O'Connell PJ, Vitalone M, et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am. J. Transplant. 2007; 7: 2757-2768.
14. Haas M, Mirocha J,. Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. Am. J. Transplant. 2011; 11: 2123-2131.
15. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 2011; 11: 2405-2413.
16. Stegall MD, Chedid MF, Cornell LD,. The role of complement in antibody-mediated rejection in kidney transplantation. Nat. Rev. Nephrol. 2012; 8: 670-678.
17. Husain S, Sis B,. Advances in the understanding of transplant glomerulopathy. Am. J. Kidney Dis. 2013; 62: 352-363.
18. Lenihan CR, Tan JC, Kambham N,. Acute transplant glomerulopathy with monocyte rich infiltrate. Transpl. Immunol. 2013; 29: 114-117.
19. Laszik Z, Kambham N, Silva FG,. Thrombotic microangiopathies. In:, Jennette JC, Olson JL, Silva FG, D'Agati VD, (eds). Heptinstall's Pathology of the Kidney, 7th edn. Philadelphia: Wolters Kluwer, 2013; 739-814.
20. Nadasdy T,. Thrombotic microangiopathy in renal allografts: the diagnostic challenge. Curr. Opin. Organ Transplant. 2014; 19: 283-292.
21. Noris M, Remuzzi G,. Thrombotic microangiopathy after kidney transplantation. Am. J. Transplant. 2010; 10: 1517-1523.
22. Sis B, Mengel M, Haas M, et al. Banff ′09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am. J. Transplant. 2010; 10: 464-471.
23. Shimizu T, Tanabe T, Shirakawa H, Omoto K, Ishida H, Tanabe K,. Acute vascular rejection after renal transplantation and isolated v-lesion. Clin. Transplant. 2012; 26 (Suppl 24): 2-8.
24. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am. J. Transplant. 2012; 12: 563-570.
25. Reeve J, Sellarés J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am. J. Transplant. 2013; 13: 645-655.
26. Sis B, Bagnasco SM, Cornell LD, et al. Isolated endarteritis and kidney transplant survival: a multicenter collaborative study. J. Am. Soc. Nephrol. 2014 Nov 7 [Epub ahead of print].
27. Wu KY, Budde K, Schmidt D, Neumayer HH, Rudolph B,. Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations. Clin. Transplant. 2014; 28: 410-418.
28. Masutani K,. Current problems in screening, diagnosis and treatment of polyomavirus BK nephropathy. Nephrology (Carlton) 2014; 19 (Suppl 3): 11-16.
29. Adam B, Randhawa P, Chan S, et al. Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): reproducibility of polyomavirus immunohistochemistry in kidney allografts. Am. J. Transplant. 2014; 14: 2137-2147.
30. Sar A, Worawichawong S, Benediktsson H, et al. Interobserver agreement for Polyomavirus nephropathy grading in renal allografts using the working proposal from the 10th Banff Conference on Allograft Pathology. Hum. Pathol. 2011; 42: 2018-2024.
31. Mengel M, Reeve J, Bunnag S, et al. Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am. J. Transplant. 2009; 9: 169-178.
32. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am. J. Transplant. 2010; 10: 2066-2073.
33. Menter T, Mayr M, Schaub S, Mihatsch MJ, Hirsch HH, Hopfer H,. Pathology of resolving polyomavirus-associated nephropathy. Am. J. Transplant. 2013; 13: 1474-1483.
34. Loupy A, Lefaucheur C, Vernerey D, et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J. Am. Soc. Nephrol. 2014; 10: 2267-2277.
35. Yang M, Rajan S, Issa AM,. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Cancer 2012; 118: 5163-5170.
36. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ,. Clinical application of the 70-gene profile: The MINDACT trial. J. Clin. Oncol. 2008; 26: 729-735.
37. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993; 44: 411-422.